Breakthrough in Oncology: Novel ADC Rolditamig Deuderuxtecan Triples Progression-Free Survival in HER2-Low Breast Cancer
MADRID — In a landmark development for the treatment of metastatic breast cancer, researchers have unveiled results from the phase III APEX-Breast01 trial, demonstrating that the novel antibody-drug conjugate (ADC)…
A New Era of Oncology: US Cancer Mortality Declines by 35% as Research Faces Political Crossroads
The landscape of oncology in the United States has undergone a profound transformation over the last three decades. According to the 2026 Cancer Progress Report released by the American Association…












